Fexuclue Gets Additional Indication for H. pylori Eradication
- Additional indication approval for Fexuclue 40mg (fexuprazan hydrochloride) for H. pylori eradication (MFDS, 2026.04.30)
- Korea's 34th new drug, already on the market
- Estimated 50% global infection rate; expected to address resistance issues
- Launch after marketing strategy formulation
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: Major Management Matters Related To Investment Decision (Domestic Product Approval For Additional Indication Of Fexuclue Tablet (Fexuclue) (Antibiotic Combination Therapy For Helicobacter pylori Eradication))
- Company: Daewoong Pharma (069620)
- Submission: Daewoong Pharma
- Receipt: 04-30-2026
- Under KRX KOSPI Market Division